Maria Fleseriu

Summary

Affiliation: Oregon Health and Science University
Country: USA

Publications

  1. ncbi request reprint Treatment options for Cushing disease after unsuccessful transsphenoidal surgery
    James K Liu
    Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Evanston Northwestern Healthcare, Evanston, Illinois 60201, USA
    Neurosurg Focus 23:E8. 2007
  2. pmc Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study
    Maria Fleseriu
    Oregon Health and Science University, Portland, OR, USA
    Endocrine 55:247-255. 2017
  3. pmc Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies
    Maria Fleseriu
    Departments of Medicine and Neurological Surgery, and Northwest Pituitary Center, Oregon Health and Science University, Mail code CH8N, 3303 SW Bond Ave, Portland, OR, 97239, USA
    Pituitary 19:643-653. 2016
  4. ncbi request reprint Medical treatment of Cushing's Disease
    Daniel Cuevas-Ramos
    Department of Endocrinology and Metabolism, Neuroendocrinology Clinic, Salvador Zubiran National Institute of Medical Sciences and Nutrition, Tlalpan, Mexico City, Mexico
    Minerva Endocrinol 41:324-40. 2016
  5. pmc Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease
    Maria Fleseriu
    Northwest Pituitary Center, Departments of Medicine and Neurological Surgery, Oregon Health and Science University, Portland, OR, USA
    Pituitary 19:138-48. 2016
  6. doi request reprint Medical treatment of Cushing disease: new targets, new hope
    Maria Fleseriu
    Department of Medicine Endocrinology, Oregon Health and Science University, Mail Code BTE 28, 3181 Southwest Sam Jackson Park Road, Portland, OR 97239, USA Department of Neurological Surgery, Oregon Health and Science University, Mail Code BTE 28, 3181 Southwest Sam Jackson Park Road, Portland, OR 97239, USA Electronic address
    Endocrinol Metab Clin North Am 44:51-70. 2015
  7. doi request reprint Medical therapy for Cushing's disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers
    Maria Fleseriu
    Departments of Medicine Endocrinology and Neurological Surgery, Northwest Pituitary Center, Oregon Health and Science University, Mail Code BTE 28, 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA
    Pituitary 18:245-52. 2015
  8. doi request reprint The role of combination medical therapy in acromegaly: hope for the nonresponsive patient
    Maria Fleseriu
    Department of Medicine, Northwest Pituitary Center, Oregon Health and Science University, Portland, Oregon 97239, USA
    Curr Opin Endocrinol Diabetes Obes 20:321-9. 2013
  9. pmc New avenues in the medical treatment of Cushing's disease: corticotroph tumor targeted therapy
    Maria Fleseriu
    Departments of Medicine and Neurological Surgery, and Northwest Pituitary Center, Oregon Health and Science University, Portland, OR 97239, USA
    J Neurooncol 114:1-11. 2013
  10. doi request reprint A new therapeutic approach in the medical treatment of Cushing's syndrome: glucocorticoid receptor blockade with mifepristone
    Maria Fleseriu
    Oregon Health and Science University, Portland, OR 97239, USA
    Endocr Pract 19:313-26. 2013

Collaborators

Detail Information

Publications40

  1. ncbi request reprint Treatment options for Cushing disease after unsuccessful transsphenoidal surgery
    James K Liu
    Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Evanston Northwestern Healthcare, Evanston, Illinois 60201, USA
    Neurosurg Focus 23:E8. 2007
    ..The indications, current results reported in the literature, and complications of each treatment modality are discussed...
  2. pmc Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study
    Maria Fleseriu
    Oregon Health and Science University, Portland, OR, USA
    Endocrine 55:247-255. 2017
    ..This analysis documents the safety of pasireotide long-acting release in patients with acromegaly enrolled in the ACCESS trial (ClinicalTrials.gov identifier: NCT01995734)...
  3. pmc Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies
    Maria Fleseriu
    Departments of Medicine and Neurological Surgery, and Northwest Pituitary Center, Oregon Health and Science University, Mail code CH8N, 3303 SW Bond Ave, Portland, OR, 97239, USA
    Pituitary 19:643-653. 2016
    ..Our aim was to better characterize the profiles of efficacy and safety of currently available adrenal steroidogenesis inhibitors, including drugs currently in development...
  4. ncbi request reprint Medical treatment of Cushing's Disease
    Daniel Cuevas-Ramos
    Department of Endocrinology and Metabolism, Neuroendocrinology Clinic, Salvador Zubiran National Institute of Medical Sciences and Nutrition, Tlalpan, Mexico City, Mexico
    Minerva Endocrinol 41:324-40. 2016
    ..Future 'on the horizon' treatment options are also discussed. ..
  5. pmc Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease
    Maria Fleseriu
    Northwest Pituitary Center, Departments of Medicine and Neurological Surgery, Oregon Health and Science University, Portland, OR, USA
    Pituitary 19:138-48. 2016
    ..The current 22-week study (LINC 2; NCT01331239) further evaluated osilodrostat in patients with Cushing's disease...
  6. doi request reprint Medical treatment of Cushing disease: new targets, new hope
    Maria Fleseriu
    Department of Medicine Endocrinology, Oregon Health and Science University, Mail Code BTE 28, 3181 Southwest Sam Jackson Park Road, Portland, OR 97239, USA Department of Neurological Surgery, Oregon Health and Science University, Mail Code BTE 28, 3181 Southwest Sam Jackson Park Road, Portland, OR 97239, USA Electronic address
    Endocrinol Metab Clin North Am 44:51-70. 2015
    ..Successful clinical management of patients with Cushing disease remains a challenge. ..
  7. doi request reprint Medical therapy for Cushing's disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers
    Maria Fleseriu
    Departments of Medicine Endocrinology and Neurological Surgery, Northwest Pituitary Center, Oregon Health and Science University, Mail Code BTE 28, 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA
    Pituitary 18:245-52. 2015
    ..Despite significant progress, there is still a need for a medical therapy that is more effective and with less adverse effects for patients with CD...
  8. doi request reprint The role of combination medical therapy in acromegaly: hope for the nonresponsive patient
    Maria Fleseriu
    Department of Medicine, Northwest Pituitary Center, Oregon Health and Science University, Portland, Oregon 97239, USA
    Curr Opin Endocrinol Diabetes Obes 20:321-9. 2013
    ..This review focuses on combination drug treatment for acromegaly patients, including novel concepts and experimental therapies, with an emphasis on the author's personal experience...
  9. pmc New avenues in the medical treatment of Cushing's disease: corticotroph tumor targeted therapy
    Maria Fleseriu
    Departments of Medicine and Neurological Surgery, and Northwest Pituitary Center, Oregon Health and Science University, Portland, OR 97239, USA
    J Neurooncol 114:1-11. 2013
    ..Pituitary-targeted medical therapies will soon play a more prominent role in treating CD, and may potentially become first-line medical therapy when surgery fails or is contraindicated. ..
  10. doi request reprint A new therapeutic approach in the medical treatment of Cushing's syndrome: glucocorticoid receptor blockade with mifepristone
    Maria Fleseriu
    Oregon Health and Science University, Portland, OR 97239, USA
    Endocr Pract 19:313-26. 2013
    ..Our objective is to review the pharmacology and clinical use of this novel agent and to discuss detailed guidance on the management of CS patients treated with mifepristone...
  11. doi request reprint Medical management of persistent and recurrent cushing disease
    Maria Fleseriu
    Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
    Neurosurg Clin N Am 23:653-68. 2012
    ..The development of new therapeutic agents has been eagerly anticipated. This article discusses the results of currently available and promising new therapeutic agents used to treat this challenging disease...
  12. doi request reprint Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome
    Maria Fleseriu
    Northwest Pituitary Center, Department of Medicine, Oregon Health and Science University, Portland, Oregon 97239, USA
    J Clin Endocrinol Metab 97:2039-49. 2012
    ..Cushing's syndrome (CS) is a disorder associated with significant morbidity and mortality due to prolonged exposure to high cortisol concentrations...
  13. doi request reprint Significant headache improvement after transsphenoidal surgery in patients with small sellar lesions
    Maria Fleseriu
    Department of Neurological Surgery, Oregon Health and Science University, Portland, Oregon, USA
    J Neurosurg 110:354-8. 2009
    ..If conventional medical management fails, transsphenoidal surgery (TSS) may be considered as an alternative treatment for intractable headaches...
  14. doi request reprint Normal hypothalamic-pituitary-adrenal axis by high-dose cosyntropin testing in patients with abnormal response to low-dose cosyntropin stimulation: a retrospective review
    Maria Fleseriu
    Department of Neurological Surgery, Oregon Health and Science University, Portland, Oregon 97239, USA
    Endocr Pract 16:64-70. 2010
    ....
  15. doi request reprint "Relative" adrenal insufficiency in critical illness
    Maria Fleseriu
    Department of Medicine, Oregon Health and Science University, 3181 Southwest Sam Jackson Park Road, BTE 472, Portland, OR 97239, USA
    Endocr Pract 15:632-40. 2009
    ..To present a recommended approach to the problem of "relative" adrenal insufficiency (RAI) in the intensive care unit (ICU)...
  16. doi request reprint Acromegaly: a review of current medical therapy and new drugs on the horizon
    Maria Fleseriu
    Department of Neurological Surgery, Division of Endocrinology, Diabetes, and Clinical Nutrition, and Northwest Pituitary Center, Oregon Health and Science University, Portland, Oregon 97239, USA
    Neurosurg Focus 29:E15. 2010
    ..Because a surgical cure can be difficult to achieve, all patients, even those with what seems to be a clinically and biochemically inactive disease, should undergo long-term biochemical testing and pituitary MR imaging...
  17. ncbi request reprint Second-line treatment for Cushing's disease when initial pituitary surgery is unsuccessful
    Maria Fleseriu
    Department of Medicine, Oregon Health and Science University, Portland, Oregon, USA
    Curr Opin Endocrinol Diabetes Obes 14:323-8. 2007
    ..It is successful in about 80% of patients in the hands of an experienced surgeon. When transsphenoidal surgery fails or is contraindicated, a second-line treatment must be chosen. The review focuses on second-line treatment options...
  18. pmc Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review
    Maria Fleseriu
    Department of Neurological Surgery, Northwest Pituitary Center, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, BTE 472, Portland, OR 97239, USA
    Pituitary 14:184-93. 2011
    ..Furthermore, patients should routinely have their GH and IGF-1 levels closely monitored and their SRL dose increased or decreased thereafter according to individual response...
  19. pmc Medical management of Cushing's disease: what is the future?
    Maria Fleseriu
    Departments of Medicine and Neurological Surgery, Northwest Pituitary Center, Oregon Health and Science University, Portland, OR, USA
    Pituitary 15:330-41. 2012
    ..Our aim is to expand awareness of current research, and the possibilities afforded by available medical treatments for this mesmerizing, but often frightful disease...
  20. doi request reprint LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study
    Xavier Bertagna
    Department of Endocrinology X B, Centre de Référence des Maladies Rares de la Surrénale, Hopital Cochin, Faculté de Médecine Paris Descartes, Universite Paris 5, Paris 75014, France Dipartimento di Medicina Clinica e Chirurgia R P, Universita Federico II di Napoli, IT 80131, Naples, Italy Department of Medicine and Neurological Surgery M F, Northwest Pituitary Center, Oregon Health and Science University, Portland, Oregon 97239 3098 Novartis Pharmaceuticals Corporation Y Z, East Hanover, New Jersey 07936 Novartis Pharmaceuticals UK Limited P R, Horsham, West Sussex, RH12 5AB, United Kingdom Novartis Institutes for BioMedical Research A T, C E W, Cambridge, Massachusetts 02139 Clinical Development M M, Oncology Business Unit, Novartis Pharma AG, CH 4002 Basel, Switzerland Department of Endocrinology, Diabetes, and Metabolism A H H, Cleveland Clinic Foundation, Cleveland, Ohio 44106 Division of Endocrinology M B, Polytechnic University of Marche, 60121 Ancona, Italy and Neuroendocrine Clinical Center B M K B, Massachusetts General Hospital, Boston, Massachusetts 02114
    J Clin Endocrinol Metab 99:1375-83. 2014
    ..As LCI699 potently inhibits 11β-hydroxylase, which catalyzes the final step of cortisol synthesis, it is a potential new treatment for Cushing's disease, the most common cause of endogenous Cushing's syndrome...
  21. doi request reprint Remission rate after transsphenoidal surgery in patients with pathologically confirmed Cushing's disease, the role of cortisol, ACTH assessment and immediate reoperation: a large single center experience
    Nadia Hameed
    Department of Medicine, Oregon Health and Science University, Portland, OR, USA
    Pituitary 16:452-8. 2013
    ..7%. ACTH measurements correlate well with cortisol. However, because no single cortisol or ACTH cutoff value excludes all recurrences, patients require long-term clinical and biochemical follow-up. Further research is needed in this area...
  22. doi request reprint Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience
    Jessica Brzana
    OHSU Northwest Pituitary Center, Oregon Health and Science University, 3181 SW Sam Jackson Park Road BTE 472, Portland, OR, 97239, USA
    Pituitary 16:490-8. 2013
    ..These immunoreactive markers should be assessed routinely on surgical specimens to assess subsequent SRL responsiveness and potential need for adjunctive therapy after surgery...
  23. pmc Pasireotide: a novel treatment for patients with acromegaly
    Daniel Cuevas-Ramos
    Department of Endocrinology and Metabolism, Neuroendocrinology Clinic, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
    Drug Des Devel Ther 10:227-39. 2016
    ..Lastly, novel therapies and new potential delivery modalities (oral octreotide) are summarized...
  24. pmc Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease: 12-month, Phase III pasireotide study
    James W Findling
    Division of Endocrinology, Metabolism, and Clinical Nutrition, Medical College of Wisconsin, W129 N7055 Northfield Drive Suite A 203, Menomonee Falls, Milwaukee, WI, 53051, USA
    Endocrine 54:516-523. 2016
    ..Pasireotide decreased LNSC levels during 12 months of treatment. Salivary cortisol may be a simple, convenient biomarker for assessing treatment response in patients with Cushing's disease...
  25. doi request reprint Recovery rate of adrenal function after surgery in patients with acromegaly is higher than in those with non-functioning pituitary tumors: a large single center study
    Chris Yedinak
    Department of Neurological Surgery, and Northwest Pituitary Center, Oregon Health and Science University, CH8N, 3303 SW Bond Ave, Portland, OR, 97239, USA
    Pituitary 18:701-9. 2015
    ..To compare hypothalamus-pituitary-adrenal (HPA) axis integrity at diagnosis and recovery after transsphenoidal surgery (TSS), in acromegaly patients, compared with tumor size matched non-functioning adenoma (NFA) patients...
  26. doi request reprint Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, GH or IGF-1 values?
    Jessica A Brzana
    Department of Medicine, Oregon Health and Science University, 3303 SW Bond Avenue, Portland, OR 97239, USA
    Pituitary 15:562-70. 2012
    ..Further studies with larger patient populations and longer follow-up are required to determine the long-term implications of discordant GH and IGF-1 value patterns...
  27. doi request reprint Relative adrenal insufficiency
    Donald L Loriaux
    Department of Medicine, Oregon Health and Science University, Portland, Oregon, USA
    Curr Opin Endocrinol Diabetes Obes 16:392-400. 2009
    ..This article will review the clinical presentation, diagnosis, and treatment of acute adrenal insufficiency and explore the concept of 'relative adrenal insufficiency' in the critically ill...
  28. doi request reprint Temozolomide for corticotroph pituitary adenomas refractory to standard therapy
    Troy H Dillard
    Division of Endocrinology, Diabetes, and Clinical Nutrition, Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
    Pituitary 14:80-91. 2011
    ..To our knowledge, this case represents the most rapid robust CA shrinkage response reported to date. Further randomized clinical trials of TMZ in the treatment of aggressive pituitary adenomas are warranted...
  29. doi request reprint Adrenal and pancreatic presentation of subdiaphragmatic retroperitoneal bronchogenic cysts
    Raphael El Youssef
    Department of Surgery, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239 3098, USA
    Arch Surg 145:302-4. 2010
    ..We present 1 case of an adrenal lesion and 1 case of a pancreatic lesion that were revealed to be retroperitoneal bronchogenic cysts after surgical extirpation...
  30. ncbi request reprint Dopamine agonist therapy induces significant recovery of HPA axis function in prolactinomas independent of tumor size: a large single center experience
    Christine G Yedinak
    Department of Neurological Surgery, Oregon Health and Science University, Portland, Oregon, USA
    Endocrine 54:191-197. 2016
    ..We show, in a large uniform study, that adrenal insufficiency significantly recovered after dopamine agonist treatment, independent of tumor size and gender in patients with prolactinomas naïve to therapy...
  31. doi request reprint Polycystic ovarian syndrome and Cushing's syndrome: a persistent diagnostic quandary
    Jessica Brzana
    Department of Medicine, Division of Endocrinology, Portland, OR, USA
    Eur J Obstet Gynecol Reprod Biol 175:145-8. 2014
    ..To determine whether clinical patterns might be useful in identifying appropriate candidates for hypercortisolism screening in women suspected of PCOS...
  32. doi request reprint Treatment of Cushing's disease: a mechanistic update
    Daniel Cuevas-Ramos
    Department of MedicinePituitary Center, Cedars Sinai Medical Center, Los Angeles, California, USANeuroendocrinology ClinicDepartment of Endocrinology and Metabolism, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, MexicoDepartments of Medicine and Neurological Surgeryand Northwest Pituitary Center, Oregon Health and Science University, 3181 SW Sam Jackson Park Road BTE 472, Portland, Oregon 97239, USA Department of MedicinePituitary Center, Cedars Sinai Medical Center, Los Angeles, California, USANeuroendocrinology ClinicDepartment of Endocrinology and Metabolism, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, MexicoDepartments of Medicine and Neurological Surgeryand Northwest Pituitary Center, Oregon Health and Science University, 3181 SW Sam Jackson Park Road BTE 472, Portland, Oregon 97239, USA
    J Endocrinol 223:R19-39. 2014
    ..A better understanding of the molecular mechanisms in CD and of HPA axis physiology should advance the development of new drugs in the future. ..
  33. doi request reprint Somatostatin receptor ligands and resistance to treatment in pituitary adenomas
    Daniel Cuevas-Ramos
    Department of MedicinePituitary Center, Cedars Sinai Medical Center, Los Angeles, California, USANorthwest Pituitary Center and Departments of Medicine and Neurological SurgeryOregon Health and Science University, 3181 SW Sam Jackson Park Road BTE 472, Portland, Oregon 97239, USA
    J Mol Endocrinol 52:R223-40. 2014
    ..Other SRL delivery modes (oral octreotide), multireceptor-targeted SRL (somatoprim) or chimeric compounds targeting dopamine D2 receptors and SSTR2 (dopastatin), are briefly discussed. ..
  34. doi request reprint Absence of immunostaining for growth hormone in a subset of patients with acromegaly
    Jason L Schroeder
    Department of Neurological Surgery, Cleveland Clinic, Cleveland, OH, 44195, USA
    Pituitary 17:103-8. 2014
    ..All patients in our small series achieved remission by multimodality therapies. Further studies are needed to evaluate the significance of our observation and whether this subset of patients follows a distinct long term clinical course...
  35. doi request reprint Giant GH-secreting pituitary adenomas: management of rare and aggressive pituitary tumors
    Ilan Shimon
    Institute of EndocrinologyRabin Medical Center, Beilinson Hospital, Petah Tiqva 49100, IsraelSackler Faculty of MedicineTel Aviv University, Tel Aviv, IsraelNeuroendocrine UnitDivision of Endocrinology and Metabolism, Hospital das Clinicas, University of Sao Paulo Medical School, Sao Paulo, BrazilNorthwest Pituitary CenterOregon Health and Science University, Portland, Oregon, USAInstitute of EndocrinologyMetabolism and Hypertension, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel Institute of EndocrinologyRabin Medical Center, Beilinson Hospital, Petah Tiqva 49100, IsraelSackler Faculty of MedicineTel Aviv University, Tel Aviv, IsraelNeuroendocrine UnitDivision of Endocrinology and Metabolism, Hospital das Clinicas, University of Sao Paulo Medical School, Sao Paulo, BrazilNorthwest Pituitary CenterOregon Health and Science University, Portland, Oregon, USAInstitute of EndocrinologyMetabolism and Hypertension, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    Eur J Endocrinol 172:707-13. 2015
    ..Giant (adenoma size ≥40 mm) GH-secreting pituitary tumors are rarely encountered and the aim of this study is to analyze different methods for managing them...
  36. doi request reprint Self-perception of cognitive function among patients with active acromegaly, controlled acromegaly, and non-functional pituitary adenoma: a pilot study
    Chris G Yedinak
    OHSU Northwest Pituitary Center, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd BTE472, Portland, OR, USA
    Endocrine 46:585-93. 2014
    ..Further research may be useful regarding patient quality of life, patient functionality during normal daily activities, and perceived dysfunction despite biological disease control...
  37. doi request reprint Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes
    Troy Dillard
    Department of Medicine, Division of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health and Science University, Portland, OR, USA
    Pituitary 13:29-38. 2010
    ..We recommend mandatory long term follow-up to monitor the development of other hormonal deficits...
  38. ncbi request reprint Diabetes insipidus, panhypopituitarism, and severe mental status deterioration in a patient with chordoid glioma: case report and literature review
    Kristine Dziurzynski
    Department of Neurological Surgery, Oregon Health and Science University, Portland, Oregon 97239, USA
    Endocr Pract 15:240-5. 2009
    ..To describe a rare progressive case of chordoid glioma clinically masquerading as idiopathic diabetes insipidus (DI)...